by Marie Daghlian | Feb 17, 2021 | Analysis, M&A
Analysis | M&A Biotech and Pharma M&A in 2020 Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. It could also be...
by Marie Daghlian | Jan 19, 2020 | Analysis, M&A
Analysis | M&A Life Sciences M&A Tops $240 Billion in 2019 This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied...
by Chris Lieu, Ph.D. | Jan 18, 2020 | Analysis, M&A
Analysis | M&A Cancer Cell Therapy M&A Over the last three years, there have been eight cancer cell therapy M&A deals for advanced first generation and next gen cancer cell therapy companies. Six of them have been completed to date. Data for this analysis...
by DealForma Analysts | Jun 20, 2019 | Analysis, Funding, M&A, Partnership Deals
Analysis | Funding | M&A | Partnership Deals Gene Therapy Deals, M&A, and Venture Funding Gene therapy deals, R&D partnerships, and acquisitions have been showing annual gains through 2018 and are on track to keep up the record in 2019. The recent...
by DealForma Analysts | Jun 13, 2019 | Analysis, M&A
Analysis | M&A Reverse Mergers in Biopharma Reverse mergers have been a relatively quick method for companies to gain a public listing as an alternative to IPOs. A private company looking to go public merges with a company that is already publicly traded and...
by Marie Daghlian | Jan 4, 2019 | Analysis, M&A
Analysis | M&A Life Sciences M&A Starts with a Bang in 2019 after Rebounding in 2018 Data for the this analysis was compiled using the DealForma database on deals. We applied initial filters for mergers and acquisitions, target company types, therapeutic...
